Anti-tumor Effect of Intravenous Administration of CRM197 for Triple-negative Breast Cancer Therapy
Autor: | Sung Ouk, Nam, Fusanori, Yotsumoto, Kohei, Miyata, Satoshi, Fukagawa, Takashi, Odawara, Sadao, Manabe, Toyokazu, Ishikawa, Masahide, Kuroki, Shin'ichiro, Yasunaga, Shingo, Miyamoto |
---|---|
Rok vydání: | 2016 |
Předmět: | |
Zdroj: | Anticancer research. 36(7) |
ISSN: | 1791-7530 |
Popis: | Heparin-binding epidermal growth factor-like growth factor (HB-EGF), which belongs to the epidermal growth factor family, is a rational therapeutic target for triple-negative breast cancer (TNBC). This study aimed to assess the anti-tumor efficacy of intravenous (i.v.) HB-EGF-specific inhibitor (CRM197) for TNBC.NOD/SCID mice were subcutaneously injected withTNBC cells, MDA-MB-231, and, then, treated with i.v. CRM197 in either dose- or frequency-dependent manners, using an advanced cancer model and an adjuvant therapy model. Tumor volume and mouse body weight were calculated weekly. Statistical significance was assessed by the Mann-Whitney U-test.Mice that received i.v. CRM197 showed a significant anti-tumor effect in dose- and frequency-dependent manners in both models. However, their body weight did not differ significantly among groups.These results suggest that i.v. CRM197 is an effective treatment for TNBC. |
Databáze: | OpenAIRE |
Externí odkaz: |
načítá se...